Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China < ...

Even before they were married, Byron and Melissa Wade understood the meaning of standing by your spouse “in sickness and in ...

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX ...

Investing.com -- Vera Therapeutics , Inc. (NASDAQ: VERA) reported a wider-than-expected loss for the first quarter of 2025, sending its shares down 2.9% in after-hours trading.

Vera reported $589.8 million in cash, cash equivalents, and marketable securities as of March 31, 2025, which the company ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Good day, ...

This second of four exclusive episodes explores whether sparsentan can leapfrog renin-angiotensin system (RAS) blockade and how emerging biomarkers may reshape management of IgA nephropathy. Nigwekar: ...

Suzanne and Mohammed, both battling end-stage kidney failure, found hope through a kidney swap at Manipal Hospital. Their ...

Chronic kidney disease is a major public health issue in India, leading to 45% deaths due to kidney failure between 2018 and ...

Department of Endocrinology and Metabolism, Affiliated Hospital of Qingdao University, Qingdao 266003, P. R. China Qingdao Key Laboratory of Thyroid, Diseases, Medical Research Center, Qingdao 266555, ...

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing ...

Despite a significant increase in net sales, Travere Therapeutics Inc (TVTX) faces hurdles with a reported net loss and ...